Almirall’s Ebglyss recommended by NICE for NHS atopic dermatitis patients

FHS
July 13, 2024
4:21 am

Almirall S.A., a global biopharmaceutical company dedicated to medical dermatology, announced today that the National Institute for Health and Care Excellence (NICE) has recommended Ebglyss (lebrikizumab) for use in moderate to severe Atopic Dermatitis in the NHS England.

Abivax releases the results of its June 5, 2023 ordinary and extraordinary general meeting – Biotech Investments

EQS-News: ABIVAX / Key word(s): AGM/EGM Abivax releases the results of its June 5, 2023 ordinary and extraordinary general meeting 08.06.2023 / 16:21 CET/CEST The

June 9, 2023

Abbott Q2 net profit falls as weaker COVID-19 test sales drag on revenue

By the numbers Q2 Sales: $10.0 billion 11% decrease year-over-year Q2 Net earnings: $1.4 billion 32% decrease year-over-year Q2 Earnings per share: $0.78 32% decrease

July 20, 2023

Resident Tregs found to remain in certain lymph nodes for a long time

The immune system is fast when it comes to fighting viruses, bacteria and other pathogens. But it also has to know when not to attack

October 30, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.